Alluvi, previously BI 4744, presents a notable breakthrough in weight loss treatment. This dual stimulator targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable effectiveness in research studies, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/